Podiatry Home
Current Issue
Archives
Supplements
Classifieds
CME
CE Articles
Subscribe
Reprints, Rights, Permission and Translation
Podiatry Today Earns Publishing Award

Dedicated to the Advancement of Footcare and Podiatry



Podiatry Today 2008 Commercial Desk Reference

View the 2008 Commercial Desk Reference for Podiatry Today
Podiatry Today

Can The HyProCure Implant Provide The Answer For Hyperpronation?
Technology In Practice:
Can The HyProCure Implant Provide The Answer For Hyperpronation?

- By Robi Garthwait, Contributing Editor


       For DPMs dealing with the common condition of hyperpronation, the HyProCure Sinus Tarsi Implant may be one of the more intriguing treatment options to date.
       Composed of medical grade titanium, the implant serves as an internal orthotic that essentially turns the negative space of the sinus tarsi into a positive space, according to the implant’s manufacturer Gramedica.
       Gramedica says the HyProCure implant is stronger than bone and requires one small incision for insertion without the need for casting after the procedure. Paul Clint Jones, DPM, has successfully implanted the HyProCure device in about 20 patients since 2006. “I have used the older generation products and none of them are able to be used and tolerated the way HyProCure is,” states Dr. Jones, who practices in Spokane, Wa., and Kellogg, Idaho.

A Closer Look At Key Benefits

One of the key benefits of the HyProCure Sinus Tarsi Implant (Gramedica) is that it “addresses the apex of the deformity of the foot,” allowing for a broader spectrum of indications, according to Paul Clint Jones, DPM.

       While medication, physical therapy and orthotics can address the symptoms of hyperpronation, Gramedica says these treatment options do not target the underlying cause. Historically, the use of implants to target the problem has also been problematic.
       “The older generation of STJ implants has a poor track record of not being tolerated and having to be removed in the adult population,” notes Dr. Jones. “(The) end result is having to do more aggressive procedures with increased risk, protracted convalescence and pain to the patient.”
       Using the HyProCure implant enables surgeons to avoid these issues, according to Dr. Jones. Gramedica maintains that surgeons have successfully used the HyProCure design since 2004 to realign the talus on the calcaneus.
       For Dr. Jones, one of the key benefits of the HyProCure is that it “addresses the apex of the deformity of the foot.” He says this allows for a broader spectrum of indications. Dr. Jones also points out that surgeons can use the implant to treat both adults and pediatric patients.
       The company says the ease of insertion makes the HyProCure stent an attractive option for practitioners. A 1.5- to 2.0-cm incision over the sinus tarsi is usually all that is necessary to implant the device. The goal of the procedure is to achieve 1 to 3 degrees of rearfoot eversion and the stent is available in several sizes to achieve this goal, according to Gramedica.
       In addition, Gramedica says the implant will not wear out, patients are usually back in regular shoes within one week of surgery and there are no limits to activities once the implant is inserted and healing has occurred.

Some Caveats To Keep In Mind
       Gramedica notes there are potential complications with this procedure. One rare complication that surgeons have observed is “sprained ankle syndrome,” due to the new stretch being placed on the outer ankle ligaments. The company says this may be a temporary symptom that will likely dissipate. However, if the ligaments do not adjust to the new positioning, Gramedica says this may require removal of the implant.
       Depending on the amount of correction one achieves with the implant, postoperative pain may also be present. Anti-inflammatory medication is recommended for six to eight weeks after the procedure to reduce discomfort, according to Gramedica.

Final Notes
       Overall, Dr. Jones says the design of the HyProCure implant and the ease of the procedure facilitates optimal results.
       “This product bridges the need to deliver the best service to my patients while minimizing the worry that I could have done something more,” emphasizes Dr. Jones.

 


Podiatry Today - ISSN: 1045-7860 - Volume 21 - Issue 6 - June 2008 - Pages: 84 - 85

August 29, 2008




About HMP Communications

HMP Communications LLC (HMP) is the authoritative source for comprehensive information and education servicing healthcare professionals. HMP’s products include peer-reviewed and non-peer-reviewed medical journals, national tradeshows and conferences, online programs and customized clinical programs. HMP is a wholly owned subsidiary of HMP Communications Holdings LLC, which also owns the North American Center for Continuing Medical Education (NACCME). NACCME provides a wide array of accredited CME offerings with industry thought leaders participating in roundtable meetings, webcasts, symposia, conferences, seminars, podcasts and satellite programs. Discover more about HMP’s products and services at www.hmpcommunications.com. ©2008 HMP Communications


© 2008 HMP Communications | Privacy Policy/Copyright | Contact Us